For Healthcare Professionals

Durvalumab and Tremelimumab for Pediatric Malignancies

clipboard-pencil

About the study

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Max Age =17 years
  2. Solid Tumors (except primary central nervous system malignant tumors): Patients must have a histopathologic confirmation of malignancy. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist
  3. Non-Hodgkin's Lymphoma, limited to primary mediastinal B-cell lymphoma and anaplastic large cell lymphoma. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist.
  4. Provision of diagnostic tumor sample mandated if available
  5. Evaluable disease
  6. No prior exposure to immune-mediated therapy
  7. Adequate organ and marrow function
  8. Life expectancy of at least 3 months

EXCLUSION CRITERIA

  1. History of allogeneic organ transplantation (exceptions may be allowed for NHL after discussion with Sponsor). History of autologous bone marrow transplant may be allowed (after discussion with Sponsor).
  2. Active or prior documented autoimmune or inflammatory disorders (exceptions)
  3. Uncontrolled intercurrent illness
  4. History of primary immunodeficiency
  5. Active infection including tuberculosis, hepatitis B, C or HIV
  6. Any unresolved toxicity NCI CTCAE version 5.0 Grade ≥2 from previous anticancer therapy (exceptions)
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-877-240-9479Email iconEmail Study Center

Study’s details


Contition

Hematological Malignancies,Pediatric Cancer,Solid Tumor Pediatric

Age

0+

Phase

Phase 1/Phase 2

Participants needed

50

Est. Completion Date

Dec 2022

Treatment type

Interventional


Sponsor

AstraZeneca

ClinicalTrials.gov identifier

NCT03837899

Study number

D419EC00001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.